恶性肿瘤患者围手术期应用贝伐珠单抗对输液港植入术术后并发症的影响  

Effect of perioperative application of bevacizumab in patients with malignant tumors on postoperative complications after infusion port implantation

作　　者：刘梅 穆宁 吴盛楠 徐悦 吕欢 王欣怡 马春华 LIU Mei;MU Ning;WU Shengnan;XU Yue;LYU Huan;WANG Xinyi;MA Chunhua(Cancer Diagnosis and Treatment Center,Tianjin People's Hospital(The First Affiliated Hospital of Nankai University),Tianjin 300121,China)

机构地区：[1]天津市人民医院(南开大学第一附属医院)肿瘤诊疗中心,天津300121

出　　处：《山东医药》2025年第3期36-39,共4页Shandong Medical Journal

基　　金：中国健康促进基金会科研课题资助项目(2019ZGJCJJLM);天津市人民医院(南开大学第一附属医院)院内基金项目(2024YJ023)。

摘　　要：目的观察恶性肿瘤患者围手术期应用贝伐珠单抗对输液港植入术术后并发症的影响。方法行输液港植入术的恶性肿瘤患者139例,根据围手术期是否应用贝伐珠单抗进行抗肿瘤血管生成治疗,分为联合贝伐珠单抗组41例与单纯治疗组98例。患者均随访6个月以上,记录并比较两组患者术后并发症发生情况,包括术后早期并发症(≤30 d)、术后晚期并发症(>30 d),计算术后并发症发生率。结果联合贝伐珠单抗组术后出现切口愈合不良1例,术后早期并发症发生率为2.44%;单纯治疗组术后出现出血4例、切口愈合不良1例,术后早期并发症发生率为5.10%;两组患者术后早期并发症发生率相比,P>0.05。联合贝伐珠单抗组术后出现导管阻塞1例、感染1例,术后晚期并发症发生率为4.88%;单纯治疗组术后出现导管移位2例,术后晚期并发症发生率为2.04%;两组患者术后晚期并发症发生率相比,P>0.05。结论恶性肿瘤患者围手术期应用贝伐珠单抗对输液港植入术术后并发症的发生未观察到明显影响。Objective To observe the effect of perioperative application of bevacizumab in patients with malignant tumors on postoperative complications after infusion port implantation.Methods According to whether bevacizumab was used for anti-tumor angiogenesis therapy in perioperative period,139 patients with malignant tumor undergoing infusion port implantation were divided into the combined bevacizumab group(41 cases)and the simple treatment group(98 cases).All patients were followed up for more than 6 months.Postoperative complications of the two groups were recorded and compared,including early postoperative complications(≤30 d)and late postoperative complications(>30 d),and we calculated the incidence of postoperative complications.Results In the combined bevacizumab group,there was 1 case of poor wound healing,and the incidence of early complications was 2.44%.In the simple treatment group,hemorrhage occurred in 4 cases and incision healing was poor in 1 case;the incidence of early postoperative complications was 5.10%.There were no significant differences in the incidence of early postoperative complications between the two groups(all P>0.05).In the combined bevacizumab group,there were 1 case of catheter obstruction and 1 case of infection,and the rate of late complications was 4.88%.In the simple treatment group,catheter displacement occurred in 2 cases,and the incidence of late complications was 2.04%.No significant differences were found in the incidence of late complications between the two groups(all P>0.05).Conclusion There is no significant effect of perioperative bevacizumab on postoperative complications in patients with malignant tumors after infusion port implantation.

关 键 词：围手术期 贝伐珠单抗 输液港植入术 术后并发症 恶性肿瘤 血管内皮生长因子 

分 类 号：R735.3[医药卫生—肿瘤]